Background-Epidemiological data on the association between body mass index (BMI) and heart failure (HF) risk among diabetic patients are rare. Methods and Results-We performed a prospective cohort study of risk for HF among 31 155 patients with type 2 diabetes mellitus (11 468 men and 19 687 women). Cox proportional hazards regression models were used to estimate the association of different levels of BMI with HF risk. During a mean follow-up of 7.8 years, 5834 subjects developed HF (2379 men and 3455 women). The multivariable-adjusted (age, race, smoking, income, and type of insurance) hazard ratios of HF associated with BMI levels (18.5-22.9, 23-24.9, 25-29.9 [reference group], 30-34.9, 35-39.9, and ≥40 kg/ m 2 ) at baseline were 0.95, 1.00, 1.00, 1.16, 1.64, and 2.02 (P trend <0.001) for men and 1.16, 1.16, 1.00, 1.23, 1.55, and 2.01 (P nonlinear <0.001) for women, respectively. When we used an updated mean value of BMI, the association of HF risk with BMI did not change. When stratified by age, race, smoking status, and use of antidiabetic drugs, the positive associations among men and the J-shaped associations among women were still present. Conclusions-Our study suggests a positive association between BMI and HF risk among men and a J-shaped association between BMI and HF risk among women with type 2 diabetes mellitus. (Circ Heart Fail. 2015;8:455-463.
D iabetes mellitus is a major public health problem, affecting ≈8% of the US population. 1 Diabetes mellitus is an independent risk factor for heart failure (HF), 2 and the presence of diabetes mellitus is designated by the current American Heart Association HF classification as stage A HF (patients at high risk for developing HF). 3 Obesity is another important public health problem worldwide. In the United States, 2 in 3 adults are currently classified as overweight or obese (body mass index [BMI] , ≥25 kg/m 2 ) and one third of them are frankly obese (BMI, ≥30 kg/m 2 ). 4 Among patients with diabetes mellitus in the United States, ≈45% to 65% of them are obese. 5 
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In the general population, obesity is a well-established risk factor for cardiovascular diseases (CVD), including HF. 6, 7 However, whether and how obesity is associated with CVD risk among diabetic patients are seldom studied. Several studies have assessed the association between BMI and the risk of total or CVD mortality in patients with type 2 diabetes mellitus, 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] but few studies have focused on the relationship between BMI and incident HF. Thus, the aim of this study was to examine the association between BMI and the risk of incident HF among patients with type 2 diabetes mellitus in the Louisiana State University Hospital-Based Longitudinal Study (LSUHLS).
Methods

Study Population
Between 1997 and 2012, the Louisiana State University Healthcare Services Division (LSUHCSD) operated 7 public hospitals and affiliated clinics in Louisiana providing quality medical care to the residents of Louisiana regardless of their income or insurance coverage. [18] [19] [20] [21] [22] [23] [24] [25] Since 1997, administrative, anthropometric, laboratory (test code, test collection date, test result values, and abnormal flag), clinical diagnosis, and medication data collected at these facilities are available in electronic form for both inpatients and outpatients. In total, ≈1.6 million patients (35% of the Louisiana population) were served by the LSUHCSD facilities. The LSUHLS was established in 2010 by using these data. 18 We established a cohort of diabetic patients who used LSUHCSD hospitals between January 1, 1999 (this could make sure all diabetes mellitus cases are newly diagnosed because the LSUHCSD data warehouse is available in electronic form since January 1, 1997), and December 31, 2009, using the International Classification of Diseases-9 (code 250). All diabetic patients in the LSUHCSD hospitals were diagnosed using the American Diabetes Association criteria: a fasting plasma glucose of ≥7.0 mmol/L or 2-hour glucose of ≥11.1 mmol/L after a 75-g 2-hour oral glucose tolerance test, or a patient with ≥1 classic symptoms plus a random plasma glucose of ≥11.1 mmol/L. 26 A validation study has been carried out for the diagnosis of diabetes mellitus in the LSUHCSD hospitals, and 20 919 patients from a sample of 21 566 hospital discharge diagnoses on the basis of International Classification of Diseases codes also had physician-confirmed diabetes mellitus using the American Diabetes Association diabetes mellitus diagnosis criteria, 26 and the agreement of diabetes mellitus diagnosis was 97%.
In this study, we only included patients who had newly diagnosed diabetes mellitus. These patients had used the LSUHSCD system for an average of 5.0 years before the diagnosis of diabetes mellitus. After excluding patients with a history of HF and stroke at baseline, 31 155 type 2 diabetic patients (11 468 men and 19 687 women) with complete data on any of the required variables for analysis were included in the present analyses. The ages of the participants were 30 to 94 years. The study and analysis plan were approved by the Pennington Biomedical Research Center and LSU Health Sciences Center Institutional Review Boards, LSU System. We did not obtain informed consent from participants involved in our study because we used anonymized data compiled from electronic medical records.
Baseline and Follow-Up Measurements
The patients' characteristics, including age of diabetes mellitus diagnosis, sex, race/ethnicity, family income, smoking status, types of health insurance, body weight, height, BMI, blood pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, hemoglobin A1c (HbA1c), estimated glomerular filtration rate, and medication (antihypertensive drug, cholesterol-lowering drug, and antidiabetic drug), within a half year of the diabetes mellitus diagnosis (baseline) and during follow-up after the diabetes mellitus diagnosis (follow-up) were extracted from the computerized hospitalization records. The updated mean values of HbA1c, low-density lipoprotein cholesterol, BMI, blood pressure, and estimated glomerular filtration rate over time were calculated for each participant from baseline to each year of follow-up. For example, at 1 year, the updated mean is the average of the baseline and 1-year values, and at 3 years, it is the average of baseline, 1-year, 2-year, and 3-year values. In the case of an event during follow-up, the period for estimating the updated mean value was from baseline to the year before this event occurred. 27 Height and weight were measured without shoes and with light clothing according to a standardized protocol. BMI was calculated by dividing weight in kilograms by the square of height in meters. In the baseline analysis, we chose the BMI measures within a half year before the diagnosis of diabetes mellitus as baseline measurement. The mean values of BMI were calculated from the date of the diagnosis of diabetes mellitus to the end of the date of the diagnosis of HF or death, or June 31, 2013.
The average number of BMI measurements during the follow-up period (from 1999 to the end of follow-up time, 2013, or to the year before HF or death event occurred) was 15.0.
Prospective Follow-Up
Follow-up information was obtained from the LSUHLS inpatient and outpatient database by using the unique number assigned to every patient who visits the LSUHCSD hospitals. Since 1997, diagnosis of HF in the LSUHCSD hospitals has been made by the treating physicians using the Framingham Criteria for HF diagnosis. 28 After clinical diagnosis of HF, echocardiography has been used for each patient with HF to support the clinical diagnosis, classify HF (ejection fraction, ≤40% or >40%), and guide the treatment according to the classification. The diagnosis of HF was the primary end point of interest of the study and was defined according to the International Classification of Diseases-9: HF (codes 402.01, 402.11, 402.91, and 428). We have conducted a validation study among 4380 patients with HF (not only diabetic patients but also nondiabetic patients) in the LSUHCSD hospitals. The physician-confirmed HF diagnosis was done at clinical visits following the first time when the patients were given a HF diagnosis by using both the Framingham Criteria for HF diagnosis and ejection fraction. 28 Of 4380 patients with HF, 2353 had an ejection fraction of ≤40% and 2027 had an ejection fraction of >40%; 2246 (95%) of 2353 HF patients with reduced ejection fraction were confirmed by using both the Framingham Criteria for HF diagnosis and ejection fraction (≤40%), and 1430 (71%) of 2027 HF patients were confirmed by using both the Framingham Criteria for HF diagnosis and ejection fraction (>40%). 28, 29 Follow-up of each cohort member continued until the date of HF, the date of the last visit if the subject stopped using the LSUHCSD hospitals, death or June 31, 2013.
Statistical Analyses
The association between BMI and incident HF was analyzed by using Cox proportional hazards models. BMI was evaluated by the following 2 ways: (1) as 6 categories (BMI, 18.5-22.9, 23-24.9, 25-29.9 [reference group], 30-34.9, 35-39.9, and ≥40 kg/m 2 ) and (2) as a continuous variable. Because there was an interaction between BMI and sex on incident HF (χ 2 =8.086; df=1; P<0.001), we stratified the sample by sex for analysis. All analyses were adjusted for age and race (model 1); age, race, smoking, income, and type of insurance (model 2); and variables in model 2 and further for low-density lipoprotein cholesterol, systolic blood pressure, HbA1c, estimated glomerular filtration rate, history of obstructive apnea, use of antihypertensive drugs, glucose-lowering agents, and cholesterol-lowering agents at baseline (in baseline analyses) and during follow-up (in the follow-up analyses; model 3). The different categories of BMI were included in the models as dummy variables, and the significance of the trend over different categories was tested in the same models with the median of each category as a continuous variable. We used restricted cubic splines in Cox models to test whether there is a nonlinear association of BMI as a continuous variable with HF risk. 30 Nonlinear trends were assessed with likelihood-ratio tests of restricted cubic splines. 30 To avoid the potential bias because of severe diseases at baseline, additional analyses were performed excluding the subjects who were diagnosed with HF and cancer during the first 2 years of follow-up. Statistical significance was considered to be P<0.05. All statistical analyses were performed with PASW for Windows, version 20.0 (IBM SPSS Inc, Chicago, III), and SAS for Windows, version 9.3 (SAS Institute, Cary, NC).
Results
General characteristics of the patients, stratified according to baseline BMI categories, are presented in Table 1 . The mean follow-up time was 7.8 years. The association of BMI with incident HF risk was positive among men and was J-shaped among women with type 2 diabetes mellitus ( Figure) . The multivariable-adjusted (age, race, smoking, income and type of insurance, Model 2) hazard ratios (95% confidence intervals) of incident HF associated with BMI levels ( Table 2) . When BMI was examined as a continuous variable, the multivariable-adjusted hazard ratios for each 1-U increase in BMI at baseline was 1.037 (95%
Figure.
Hazard ratios of heart failure by body mass index (BMI) at baseline and during follow-up among men and women with type 2 diabetes mellitus. Hazard ratios are adjusted for age, race, type of health insurance, income, and smoking.
confidence interval, 1.032-1.042) for men and 1.032 (95% confidence interval, 1.028-1.036) for women. After further adjustment for low-density lipoprotein cholesterol, systolic blood pressure, HbA1c, GFR, history of obstructive apnea, use of antihypertensive drugs, glucose-lowering agents, and cholesterol-lowering agents (Model 3), the association did not change.
When we performed additional analyses by using an updated mean value of BMI, we found a positive association between BMI and HF risk among men (P trend <0.001) and a J-shaped association between BMI and HF risk among women (P nonlinear <0.001; Table 2 ). Women who had low body weight (BMI, <23) and obesity (BMI, ≥30) had an increased risk of HF compared with overweight women (BMI, 25-29.9). After excluding subjects who were diagnosed with HF and cancer during the first 2 years of follow-up (n=1812), the positive association between BMI and HF risk among men and the J-shaped association between BMI and HF risk among women did not change (data not shown).
When stratified by age, race, smoking status, and use of antidiabetic drugs, the multivariable-adjusted positive association between BMI and HF risk was present among men in most of the subgroups (Table 3) , and the multivariableadjusted J-shaped association between BMI and HF risk was present among women in some of the subgroups (Table 4 ). As ejection fraction is an important marker for HF diagnosis and treatment, we also conducted additional analyses of BMI with incident HF stratified by ejection fractions of ≤40% and >40% BMI indicates body mass index; CI, confidence interval; HR, hazard ratio; HbA1c, hemoglobin A1c; and LDL; low-density lipoprotein. *Adjusted for age and race. †Adjusted for age, race, types of insurance, income, and smoking. ‡Adjusted for age, race, types of insurance, income, smoking, LDL cholesterol, systolic blood pressure, HbA1c, glomerular filtration rate, history of obstructive sleep apnea, use of antihypertensive drugs, glucose-lowering agents, and cholesterol-lowering agents at baseline (in baseline analyses) and during follow-up (in the follow-up analyses).
( Table 5 ). The positive association was found in incident HF defined as a preserved ejection fraction of ≤40% among men or HF defined as a preserved ejection fraction of >40% among both men and women.
Discussion
Our study found a positive association between BMI and HF risk among men and a J-shaped association between BMI and HF risk among women with type 2 diabetes mellitus. A significantly increased risk of HF was observed among men with BMI ≥30 kg/m 2 and among women with BMI ≥30 and 18.5 to 22.9 kg/m 2 , compared with those with BMI 25 to 29.9 kg/m 2 .
Several previous studies have assessed the association between BMI and all-cause or CVD mortality among patients with diabetes mellitus, and the results are inconsistent, including inverse associations, 5,8-10 positive associations, 11, 12 U-shaped associations, [13] [14] [15] or no association. 16, 17 The limitations of these studies included short follow-up duration, [14] [15] [16] a small number of deaths, 5, 17 suboptimal control for smoking status and pre-existing chronic conditions, 5,14-17 and use of BMI up to several decades before diabetes mellitus diagnosis. 14, 16, 17 Considering all of the above limitations, a recently published article from 2 large prospective cohort studies concluded a J-shaped association between BMI and mortality among all diabetic participants and among those who had ever smoked, and a direct linear relationship among those who had never smoked. 31 However, as the subjects in this study were female nurses and male health professionals who were Adjusted for age, race, income, type of insurance, and smoking at baseline (in the baseline analyses) and during follow-up (in the follow-up analyses) other than the variable for stratification. BMI indicates body mass index.
*Among individuals who had ejection fraction measured at baseline.
at higher socioeconomic status, the results are limited to be generalized to the overall population.
Our study found a positive association between BMI and HF risk among men and a J-shaped association between BMI and HF risk among women with type 2 diabetes mellitus. Diabetic patients with BMI ≥30 kg/m 2 have a significantly increased risk of HF when compared with those with BMI 25 to 29.9 kg/m 2 . There is substantial evidence supporting the biological plausibility of a positive association between excess adiposity and the risk of CVD, including HF, 6,7 and the mechanism was suggested that adipose tissue can release a large number of cytokines and bioactive mediators which play important roles in the pathogenesis of many obesity-related CVDs. 32 It is noteworthy that among women with diabetes mellitus, a significantly increased risk of HF was also observed among those with BMI 18.5 to 22.9 kg/m 2 when compared with those with BMI 25 to 29.9 kg/m 2 . The reason for this increased risk of HF among low-normal weight patients might be that diabetic patients with normal weight have metabolically obese normal weight, who have hyperinsulinemia, insulin resistance, and dyslipidemia. 33 There is another hypothesis that lean individuals may have a stronger genetic predisposition of type 2 diabetes mellitus. 34 We have conducted the following analyses to ensure the rigor of the results. First, at baseline, people with a history of stroke or HF before the diagnosis of diabetes mellitus were excluded. Second, after further control of potential physiological effects of excess fatness, such as hypertension, HbA1c, and dyslipidemia, the association did not change. Third, we performed a sensitivity analysis by excluding subjects who Adjusted for age, race, income, type of insurance, and smoking at baseline (in the baseline analyses) and during follow-up (in the follow-up analyses) other than the variable for stratification. BMI indicates body mass index.
were diagnosed with HF and cancer during the first 2 years of follow-up, as these subjects might have been seriously sick or had reduced BMI, and we found that the association did not change. Finally, we stratified by race, age, smoking status, and the use of glucose-lowering agents, and the association between BMI and incident HF risk was similar among the different subgroups.
In recent years, some studies have focused on the role of smoking in the analyses of body weight with mortality because smoking is associated with decreased body weight but with an increased risk of death. 35 The attenuated relationship between BMI and mortality among smokers has been observed both in the general population 36 and in patients with diabetes mellitus. 31 However, it is unclear whether this difference between smokers and nonsmokers represents a biological difference or is largely because of bias. 35 Contrary to the above studies, our study found no effect modification according to smoking status. Future studies are needed to clarify whether there is biological difference related to smoking.
There are several strengths in our study. First, it is the first large-sample study with long follow-up time focusing on BMI and incident HF among diabetic patients. Second, we have used BMI measurements at baseline and updated mean values, which can avoid potential bias from a single-baseline measurement. Third, participants in this study used the same public healthcare system that minimizes bias related to accessibility to healthcare. Finally, all data in analyses (like BMI) are from administrative databases that minimize the differential recall bias. This study also has limitations. First, our analysis was not performed on a representative sample of diabetic patients, which limits the generalizability of the results. However, LSUHCSD hospitals were public hospitals and covered >1.6 million patients, most of whom are low income people in Louisiana. Thus, the results of this study will have wide applicability for diabetic patients with low income in the United States. Second, although diagnosis of HF in the LSUHCSD hospitals has been combined with both the Framingham Criteria for Heart Failure diagnosis and echocardiogram, there are limitations in the diagnosis of HF with preserved ejection fraction, which have been discussed by a recent review. 37 Third, although our analyses adjusted for an extensive set of confounding factors, residual confounding because of the measurement error in the assessment of confounding factors, unmeasured factors, such as physical activity and education, and dietary factors, cannot be excluded.
In summary, this large hospital-based cohort study suggested a positive association between BMI and HF risk among men and a J-shaped association between BMI and HF risk among women with type 2 diabetes mellitus, regardless of age, race, smoking status, and use of glucose-lowering agents. Adjusted for age, race, income, type of insurance, and smoking at baseline (in the baseline analyses) and during follow-up (in the follow-up analyses). BMI indicates body mass index.
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